LUMO - Lumos Pharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Austin,
United States
Type: Equity
LUMO price evolution
LUMO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.8 | $23.18 | $35.08 | |
| Short term investments | $1 | |||
| Net receivables | $0.17 | $0.17 | $0.18 | $0.21 |
| Inventory | ||||
| Total current assets | $17.27 | $20.89 | $27.54 | $40.03 |
| Long term investments | ||||
| Property, plant & equipment | $0.19 | $0.46 | $0.53 | $0.6 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.46 | $0.53 | $0.6 | |
| Total investments | $1 | |||
| Total assets | $17.46 | $21.36 | $28.08 | $40.64 |
| Current liabilities | ||||
| Accounts payable | $1.46 | $0.34 | $0.57 | $0.89 |
| Deferred revenue | ||||
| Short long term debt | $0.3 | $0.29 | $0.28 | |
| Total current liabilities | $6.5 | $4.93 | $4.41 | $7.03 |
| Long term debt | $0.14 | $0.23 | $0.3 | |
| Total noncurrent liabilities | $6.14 | $6.22 | $6.3 | |
| Total debt | $0.45 | $0.52 | $0.58 | |
| Total liabilities | $12.55 | $11.08 | $10.64 | $13.33 |
| Shareholders' equity | ||||
| Retained earnings | -$186.98 | -$179.51 | -$171.96 | -$161.52 |
| Other shareholder equity | ||||
| Total shareholder equity | $10.28 | $17.44 | $27.3 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $35.08 | $56.01 | $94.81 | $98.68 |
| Short term investments | $1 | $11.35 | ||
| Net receivables | $0.21 | $0.22 | $0.13 | $26.15 |
| Inventory | ||||
| Total current assets | $40.03 | $72.01 | $99.68 | $128.45 |
| Long term investments | ||||
| Property, plant & equipment | $0.6 | $0.28 | $0.64 | $0.58 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.6 | $0.28 | $0.64 | $0.58 |
| Total investments | $1 | $11.35 | ||
| Total assets | $40.64 | $72.29 | $100.31 | $129.03 |
| Current liabilities | ||||
| Accounts payable | $0.89 | $0.28 | $0.61 | $0.24 |
| Deferred revenue | ||||
| Short long term debt | $0.28 | $0.23 | $0.35 | $0.32 |
| Total current liabilities | $7.03 | $6.71 | $5.13 | $6.46 |
| Long term debt | $0.3 | $0.2 | ||
| Total noncurrent liabilities | $6.3 | $6 | $6.21 | $6 |
| Total debt | $0.58 | $0.23 | $0.56 | $0.32 |
| Total liabilities | $13.33 | $12.71 | $11.34 | $12.46 |
| Shareholders' equity | ||||
| Retained earnings | -$161.52 | -$127.48 | -$96.42 | -$65.99 |
| Other shareholder equity | -$0.01 | |||
| Total shareholder equity | $27.3 | $59.58 | $88.98 | $116.57 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.73 | $0.49 | $0.17 | $0.83 |
| Cost of revenue | ||||
| Gross Profit | $0.49 | $0.17 | $0.83 | |
| Operating activities | ||||
| Research & development | $4.63 | $7.25 | $6.66 | |
| Selling, general & administrative | $3.68 | $3.78 | $4.17 | |
| Total operating expenses | $8.37 | $8.31 | $11.03 | $10.83 |
| Operating income | -$7.82 | -$10.86 | -$10 | |
| Income from continuing operations | ||||
| EBIT | -$7.55 | -$10.44 | -$9.46 | |
| Income tax expense | ||||
| Interest expense | $0.17 | |||
| Net income | ||||
| Net income | -$7.47 | -$7.55 | -$10.44 | -$9.46 |
| Income (for common shares) | -$7.55 | -$10.44 | -$9.46 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.05 | $1.52 | $0.23 | $0.17 |
| Cost of revenue | ||||
| Gross Profit | $2.05 | $1.52 | $0.23 | $0.17 |
| Operating activities | ||||
| Research & development | $22.1 | $17.86 | $16.25 | $9.21 |
| Selling, general & administrative | $16.57 | $15.71 | $15.33 | $17.27 |
| Total operating expenses | $38.66 | $33.56 | $31.58 | $26.47 |
| Operating income | -$36.61 | -$32.04 | -$31.35 | -$26.3 |
| Income from continuing operations | ||||
| EBIT | -$34.06 | -$31.07 | -$31.07 | -$19.64 |
| Income tax expense | -$0.03 | -$0.01 | -$0.64 | -$13.97 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$34.03 | -$31.06 | -$30.43 | -$5.66 |
| Income (for common shares) | -$34.03 | -$31.06 | -$30.43 | -$6.31 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$7.55 | -$10.44 | -$9.46 | |
| Operating activities | ||||
| Depreciation | $0 | $0 | $0.02 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.39 | $0.58 | $0.52 | |
| Total cash flows from operations | -$6.38 | -$12.89 | -$7.39 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $1 | $6.17 | ||
| Total cash flows from investing | $1 | $1 | $6.17 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $0.74 | ||
| Net borrowings | ||||
| Total cash flows from financing | $1.72 | -$0.01 | $0.74 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$21.56 | -$6.38 | -$11.9 | -$0.48 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$34.03 | -$31.06 | -$30.43 | -$5.66 |
| Operating activities | ||||
| Depreciation | $0.04 | $0.05 | $0.2 | $0.58 |
| Business acquisitions & disposals | $84.18 | |||
| Stock-based compensation | $2.32 | $2.32 | $2.88 | $1.07 |
| Total cash flows from operations | -$31.09 | -$26.62 | -$29.65 | -$23 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | $25.97 | $32.47 | |
| Investments | $10.74 | -$11.34 | ||
| Total cash flows from investing | $10.74 | -$11.36 | $25.97 | $116.65 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.55 | -$0.77 | -$0.08 | $0.1 |
| Net borrowings | -$0.03 | |||
| Total cash flows from financing | -$0.58 | -$0.82 | -$0.19 | $0.07 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$20.93 | -$38.8 | -$3.87 | $93.73 |
News
Fundamentals
| Market cap | $37.53M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 8.65M |
| Revenue | $2.21M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$34.92M |
| Revenue Q/Q | 10.27K% |
| Revenue Y/Y | 26.94% |
| P/E ratio | -1.07 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 17.02 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$4.04 |
|---|---|
| ROA | -129.88% |
| ROE | N/A |
| Debt/Equity | 0.49 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.66 |
| Quick ratio | N/A |